Literature DB >> 26286452

BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment.

Svetlana A Protsenko1, Anna I Semionova1, Yuri I Komarov1, Svetlana N Aleksakhina1, Alexandr O Ivantsov1, Aglaya G Iyevleva2, Evgeny N Imyanitov3,4,5,6.   

Abstract

We report a patient with a metastatic relapse of clear cell sarcoma, whose tumor harbored BRAF V600E mutation. Standard chemotherapy with doxorubicin and ifosfamide failed to slow the disease progression. Subsequent administration of vemurafenib (960 mg twice a day) resulted in complete tumor response after 8 weeks of treatment. Literature data on the use of vemurafenib and dabrafenib in non-melanoma BRAF-mutated tumors are reviewed.

Entities:  

Keywords:  BRAF; Clear cell sarcoma; Review; Vemurafenib

Mesh：

Substances：

Year:  2015        PMID： 26286452     DOI： 10.1007/s10637-015-0280-0

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  54 in total

1.  Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma.

Authors:  Solange Peters; Olivier Michielin; Stefan Zimmermann
Journal:  J Clin Oncol       Date:  2013-06-03       Impact factor: 44.544

2.  BRAFV600 mutant non-small-cell lung cancer resistant to Vemurafenib.

Authors:  Fadi El Karak; Tarek Assi; Hampig Raphael Kourie; Elie El Rassy; Ralph Chebib; Maya Ghor; Samer Tabchi
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

3.  Use of vemurafenib in anaplastic thyroid carcinoma: a case report.

Authors:  Kristen A Marten; Vinay K Gudena
Journal:  Cancer Biol Ther       Date:  2015-07-15       Impact factor: 4.742

4.  Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma.

Authors:  Frederic J Kaye; Alison M Ivey; Walter E Drane; William M Mendenhall; Robert W Allan
Journal:  J Natl Cancer Inst       Date:  2014-12-03       Impact factor: 13.506

5.  Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.

Authors:  J P Sharman; J Chmielecki; D Morosini; G A Palmer; J S Ross; P J Stephens; J Stafl; V A Miller; S M Ali
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-06-11

6.  Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib.

Authors:  Ahmed Idbaih; Karima Mokhtari; Jean-François Emile; Damien Galanaud; Hayat Belaid; Simon de Bernard; Neila Benameur; Vlad-Ciprian Barlog; Dimitri Psimaras; Jean Donadieu; Catherine Carpentier; Nadine Martin-Duverneuil; Julien Haroche; Loic Feuvret; Noel Zahr; Jean-Yves Delattre; Khê Hoang-Xuan
Journal:  Neurology       Date:  2014-09-10       Impact factor: 9.910

7.  Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib.

Authors:  V Vergote; D Dierickx; A Janssens; G Verhoef; T Tousseyn; P Vandenberghe; P Wolter; M Delforge
Journal:  Ann Hematol       Date:  2014-05-27       Impact factor: 3.673

8.  Receptor tyrosine kinase pathway analysis sheds light on similarities between clear-cell sarcoma and metastatic melanoma.

Authors:  Tiziana Negri; Silvia Brich; Elena Conca; Fabio Bozzi; Marta Orsenigo; Silvia Stacchiotti; Marco Alberghini; Valentina Mauro; Alessandro Gronchi; Giuseppina F Dusio; Giuseppe Pelosi; Piero Picci; Paolo G Casali; Marco A Pierotti; Silvana Pilotti
Journal:  Genes Chromosomes Cancer       Date:  2011-11-01       Impact factor: 5.006

9.  Targeting the BRAF V600E mutation in multiple myeloma.

Authors:  Mindaugas Andrulis; Nicola Lehners; David Capper; Roland Penzel; Christoph Heining; Jennifer Huellein; Thorsten Zenz; Andreas von Deimling; Peter Schirmacher; Anthony D Ho; Hartmut Goldschmidt; Kai Neben; Marc S Raab
Journal:  Cancer Discov       Date:  2013-04-23       Impact factor: 39.397

10.  Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib.

Authors:  Siraj M Ali; Je He; Wade Carson; Phil J Stephens; Joseph Fiorillo; Doron Lipson; Gary A Palmer; Jeffrey S Ross; Vincent A Miller; Jeffrey Sharman
Journal:  Case Rep Oncol       Date:  2014-05-24
View more
  9 in total

1.  Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan.

Authors:  Sergey V Silkin; Sergey S Startsev; Marina E Krasnova; Grigory A Raskin; Natalia V Mitiushkina; Aglaya G Iyevleva; Anna P Sokolenko; Evgeny N Imyanitov
Journal:  J Gastrointest Cancer       Date:  2016-12

2.  Targeting BRAF mutants in clear-cell sarcomas of soft tissue: beyond sarcoma or melanoma classification.

Authors:  Arnaud Uguen; Pascale Marcorelles; Marc De Braekeleer
Journal:  Invest New Drugs       Date:  2016-01-08       Impact factor: 3.850

3.  Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas.

Authors:  Sarina Gouravan; Leonardo A Meza-Zepeda; Ola Myklebost; Eva W Stratford; Else Munthe
Journal:  Int J Mol Sci       Date:  2018-03-23       Impact factor: 5.923

Review 4.  BRAF mutation and its inhibitors in sarcoma treatment.

Authors:  Haotian Liu; Nahar Nazmun; Shafat Hassan; Xinyue Liu; Jilong Yang
Journal:  Cancer Med       Date:  2020-05-31       Impact factor: 4.452

Review 5.  Molecular Diagnostics in Clinical Oncology.

Authors:  Anna P Sokolenko; Evgeny N Imyanitov
Journal:  Front Mol Biosci       Date:  2018-08-27

6.  Identification of a novel MTAP-RAF1 fusion in a soft tissue sarcoma.

Authors:  J Kevin Hicks; Evita Henderson-Jackson; Julia Duggan; David M Joyce; Andrew S Brohl
Journal:  Diagn Pathol       Date:  2018-10-12       Impact factor: 2.644

Review 7.  Translating Molecular Profiling of Soft Tissue Sarcomas into Daily Clinical Practice.

Authors:  Celine Jacobs; Lore Lapeire
Journal:  Diagnostics (Basel)       Date:  2021-03-14

Review 8.  Molecular targeted therapy for advanced or metastatic soft tissue sarcoma.

Authors:  Jin Yuan; Xiaoyang Li; Shengji Yu
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

Review 9.  Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives.

Authors:  Svetlana N Aleksakhina; Evgeny N Imyanitov
Journal:  Int J Mol Sci       Date:  2021-10-10       Impact factor: 5.923
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.